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Abstract
The objective of this study was to explore associations between alcohol consumption and disease activity in axial spondy-
loarthritis (axSpA). We conducted a cross-sectional study of axSpA participants meeting the ASAS criteria. Associations 
between self-reported current alcohol use and disease activity (BASDAI, spinal pain, ASDAS), functional impairment 
(BASFI), and quality of life were explored using multivariable linear models, adjusting for age, gender, symptom duration, 
use of TNF inhibition therapy, smoking, deprivation, and anxiety and depression (A&D). Within alcohol drinkers, effect of 
increased alcohol intake (defined as > 14 units/week) was explored with moderate drinking (≤ 14 units/week) as reference. 
The study cohort comprised 229 axSpA patients and 76% were male with mean age 46.5 years (SD ± 13.8). Alcohol drinking 
was reported by 64%, with a median of 6 units per week among drinkers. Compared with non-drinkers, drinkers had lower 
BASDAI (β = − 0.83; 95% CI − 1.49, − 0.17), ASDAS (β = − 0.36; 95% CI − 0.66, − 0.05) and BASFI (β = − 1.40; 95% 
CI − 2.12, − 0.68). These associations were in contrast to, and independent of, the detrimental effects of smoking, depres-
sion, and deprivation. Subgroup analysis in alcohol drinkers did not reveal significant associations between disease severity 
and increased alcohol intake. Stratified analyses by smoking revealed that in never-smokers without depression, alcohol was 
associated with greater reduction in disease activity: BASDAI (β = − 1.69; 95% CI − 2.93, − 0.45), ASDAS (β = − 0.60; 95% 
CI − 1.18, − 0.02). Favourable axSpA disease activity and function were observed in association with alcohol consumption 
in this cross-sectional study. Longitudinal study is required to explore whether this relationship is due to biological effects 
of alcohol on disease process or disease-associated behaviour modification.
Keywords Axial spondyloarthritis · Ankylosing spondylitis · Alcohol · Disease activity · Functional impairment · Quality 
of life
Introduction
Axial spondyloarthritis (axSpA) is a chronic inflammatory 
disease predominantly affecting the axial skeleton. Poten-
tially modifiable environmental risk factors for increased 
disease activity and severity have received much research 
interest. There is emerging evidence that cigarette smoking 
is associated with a more severe disease phenotype in axSpA 
[1, 2]. Some studies have also suggested that dietary modifi-
cation may reduce disease activity in AS [3]. However, the 
impact of alcohol consumption on axSpA disease activity 
and functional impairment has not been extensively studied, 
despite one study identifying an association between alcohol 
intake with radiographic damage in early disease [4].
Moderate alcohol intake has often been reported to ben-
eficial for health [5] and is associated with reduced CRP in 
the general population [6]. In rheumatoid arthritis, alcohol 
consumption is inversely associated with risk [7], severity 
[8], extra-articular manifestations [9], and radiographic pro-
gression [10]. However, in psoriasis and psoriatic arthritis 
the converse in observed: alcohol consumption was associ-
ated with increased disease susceptibility independent of 
smoking [11, 12]. Therefore, the role of alcohol in inflam-
matory diseases, and particularly in axSpA, is far from clear. 
Lifestyle behaviours such as alcohol intake and smoking are 
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frequently associated with demography and socioeconomic 
factors as well as psychological status. In any study examin-
ing impact of alcohol on inflammatory disease, adjustments 
for these potential confounding variables need to be con-
sidered. The aim of this study was to explore associations 
between alcohol consumption and disease activity and func-
tion in axSpA.
Methods
Consecutive axSpA patients attending a tertiary referral 
spondyloarthritis service in Liverpool, UK, were recruited 
between 2010 and 2015. Patients were included if they ful-
filled the ASAS criteria for axial SpA. Clinical data were 
collected at the initial clinical assessment including: age, 
gender, body mass index (BMI), smoking status, pack-years; 
meeting modified New York criteria for AS, symptom dura-
tion, duration since diagnosis, HLA-B27, extra-axial fea-
tures; current use of NSAIDs, and tumour necrosis fac-
tor inhibition therapy (TNFi). Socioeconomic status was 
approximated using index of multiple deprivation (IMD) 
based on post-codes [13]. Decile 1 relates to the top 10% 
most deprived areas, whilst decile 10 represents the least 
deprived areas.
At the initial clinical assessment, participants reported 
frequency of drinking and estimated their average weekly 
alcohol consumption in units, with 1 unit is equal to 10 ml 
or 8 g of pure alcohol. They were categorised as drink-
ers or non-drinkers (including previous drinkers that have 
stopped for > 1 year). “Occasional” and “social” drink-
ers were classed as drinkers. Alcohol intake was used to 
divide drinkers into two groups, which, in this study, were 
labelled “moderate” (≤ 14 units/week) or “heavy” drink-
ers (> 14 units/week), for both genders as per current UK 
Department of Health guidelines [14]. This dichotomisation 
was performed, because retrospective patient estimates of 
units/week  were unlikely to be accurate and were often in 
multiples of 7.
Disease activity and functional status were assessed using 
numeric rating scale versions of the Bath AS Disease Activ-
ity Index (BASDAI), spinal pain, and Bath AS Functional 
Index (BASFI). AS disease activity score (ASDAS) was 
introduced after study commencement and was, therefore, 
missing at random. Quality of life was assessed by EuroQol 
(EQ5D-3L) using UK value sets and overall health status 
visual analogue scale (EQ-VAS). EQ5D index is anchored at 
1 when there are no problems in all domains, and 0 as death 
[15]. Anxiety and depression (A&D) domain was extracted 
from EQ5D-3L and treated as a binomial variable recording 
the presence or absence of any self-reported A&D. Blood 
samples were taken on the day of assessment for ESR and 
CRP.
Analysis
Statistical analyses were performed using Stata13. Com-
parison of patient and disease characteristics between 
drinking status and quantity were performed using Stu-
dent’s t test for normally distributed, Mann–Whitney U 
test for non-normal, and Chi-squared or Fisher’s exact test 
for categorical variables.
Multivariable linear models were generated to explore 
the association between drinking status as the dichoto-
mous independent variable and each measure of disease 
activity in turn. Models were adjusted for age, gender, 
symptom duration, use of TNFi, ever-smoking, IMD, and 
A&D. Additional models were generated to examine inter-
actions between all covariates. Within drinkers, multivari-
able linear models with the above covariates were used 
to compare heavy drinkers to those reporting moderate 
intake. For sensitivity analysis, gender-specific tertiles of 
units/week were also generated within drinkers to explore 
intake quantity in multivariable models, using the lowest 
tertile as the reference group.
EQ5D index could not be adequately transformed and 
was, therefore, dichotomised by its median and analysed 
using logistic regression with the above covariates except 
A&D. AS diagnosis, use of NSAIDs, and HLA-B27 did not 
improve the model (assessed by likelihood ratio test) and 
were, therefore, not included. ESR and CRP were log-trans-
formed prior to regression. Missing data were not imputed.
This study complies with the Declaration of Helsinki 
and was approved by the UK Research Ethics Committee 
(15/LO/1519).
Results
The study recruited 238 participants with established axSpA 
of whom 229 (96%) had complete alcohol history. The 
cohort was predominantly male (76%) with mean age of 
46.5 years (SD ± 13.8) and 83% met modified New York cri-
teria for AS. The median symptom duration was 17.1 years 
[interquartile range (IQR) 8.4, 29.3]. HLA-B27 was meas-
ured in 141 (62%) and of these 60% were positive. TNFi 
treatment was used by 76 (33%). The median BASDAI was 
5.7 (IQR 3.3, 7.6) and BASFI 5.7 (IQR 3.3, 7.6). ASDAS 
was available for 182 (79%) participants with mean of 2.7 
(SD ± 1.1). Alcohol drinking was reported by 147 (64%). 
Amongst drinkers, the median quantity was 6 units per week 
(IQR 2, 20). Only two participants described themselves as 
ex-drinkers. There were no differences in participant or dis-
ease characteristics between those with alcohol history and 
the minority without (data not shown).
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Participant and disease characteristics are shown in 
Table  1. Male participants were more likely to report 
drinking than females. No significant differences were 
seen between alcohol status and age, symptom duration, 
and proportion of AS, BMI, or extra-axial features, includ-
ing psoriasis. There was no observed association between 
drinking and smoking. Most markers of disease severity 
were significantly worse in non-drinkers.
Compared to moderate drinkers, heavy drinkers were 
more frequently male, were more likely to be smokers, 
and had greater pack-year smoking exposure. There were 
no differences in age and socioeconomic status. However, 
heavy drinkers reported significantly worse quality of life 
and in addition were more likely to be using TNFi therapy 
at the time of assessment. Alcohol status and quantity 
were not associated with IMD. However, ever-smoking 
(P = 0.01) and A&D (P = 0.01) were both associated with 
higher deprivation.
There was no association between alcohol drinking and 
A&D (P = 0.51), but there was a trend towards more A&D 
in heavy drinkers (64 vs 47%, P = 0.07). Ever-smokers more 
commonly reported A&D than never-smokers (54 vs 46%, 
P = 0.03). There was no association between any alcohol 
use and smoking (P = 0.72). However, heavy drinkers more 
frequently reported cigarette smoking than moderate drink-
ers (75 vs 40%, P = 0.01).
In multi-adjusted linear models without interaction terms, 
alcohol drinking was associated with lower disease activ-
ity (BASDAI β = − 0.83, 95% CI − 1.49, − 0.17; ASDAS 
β = − 0.36, 95% CI − 0.66, − 0.05) and functional impair-
ment (BASFI β = − 1.40, 95% CI − 2.12, − 0.68) (Table 2). 
As covariates in this model, A&D was associated with 
Table 1  Patient and disease characteristics compared between alcohol status and quantity categories
Statistically significant results are presented in bold
Data are presented in n (%), mean (SD), and median [IQR]
A&D anxiety and depression, IMD index of multiple deprivation, ASDAS Ankylosing Spondylitis Disease Activity Score, EQ EuroQoL, IBD 
inflammatory bowel disease, TNFi TNF inhibition therapy, NSAID non-steroidal anti-inflammatory drugs
a BMI complete data in 182; HLAB27 status known in 141; ASDAS in 182; CRP in 222; ESR in 221, EuroQol scores, and A&D in 213
No alcohol Alcohol drinker P value Moderate drinking 
(≤ 14 units/week)
Heavy drinking 
(> 14 units/week)
P value
Number of patients 82 (36%) 147 (64%) 104 (71%) 43 (29%)
Age 45.5 (14.3) 47.0 (13.6) 0.409 46.1 (14.0) 49.4 (12.4) 0.177
Male gender 51 (62%) 122 (83%) < 0.001 79 (76%) 43 (100%) < 0.001
BMIa 28.6 (4.7) 28.0 (5.7) 0.494 27.6 (5.8) 28.9 (5.3) 0.261
IMD decile 2 [1, 5] 2 [1, 6] 0.143 3 [1, 6] 2 [1, 5] 0.889
AS diagnosis 68 (83%) 122 (83%) 0.990 85 (82%) 37 (86%) 0.526
HLA-B27  statusa 30 (53%) 55 (65%) 0.126 40 (65%) 15 (68%) 0.756
Symptom duration (years) 16.2 [6.5, 29.3] 17.2 [9.1, 29.6] 0.391 16.8 [8.4, 29.2] 20.4 [10.5, 32.5] 0.317
Diagnosis duration (years) 4.0 [0.7, 12.6] 5.2 [0.9, 15.2] 0.177 3.6 [0.8, 14.4] 8.0 [1.7, 17.6] 0.087
Ever-smoking 37 (45%) 70 (48%) 0.717 42 (40%) 28 (65%) 0.006
Pack-years 0 [0, 15] 0 [0, 20] 0.953 0 [0, 10] 10 [0, 20] 0.008
Self-reported A&D 43 (57%) 71 (52%) 0.505 46 (47%) 25 (64%) 0.070
BASDAI 6.7 [3.7, 8.3] 5.3 [3, 7.2] 0.002 5.3 [2.9, 7.2] 5.1 [3.1, 7.2] 0.914
Spinal pain 7.0 [4.0, 9.0] 5.0 [3.0, 8.0] 0.008 5 [3, 8] 6 [2, 8] 0.888
ASDASa 2.93 (1.22) 2.57 (1.09) 0.040 2.49 (1.08) 2.78 (1.10) 0.199
BASFI 6.5 [4.2, 8.4] 5.0 [2.1, 7.3] 0.001 4.9 [2, 7.1] 5.7 [2.4, 7.5] 0.355
CRP (mg/L)a 3 [1, 10] 3 [1, 7] 0.582 3 [1, 7] 3 [1, 6] 0.434
ESR (mm/hr)a 9 [5, 23] 8 [5, 19] 0.412 8 [5, 20] 6.5 [2, 13.5] 0.113
EQ5D  indexa 0.52 [0.01, 0.69] 0.59 [0.09, 0.76] 0.068 0.68 [0.16, 0.80] 0.16 [− 0.07, 0.76] 0.008
EQ-VASa 53.1 (21.9) 43.7 (25.0) 0.008 41.8 (2.83) 46.2 (3.30) 0.315
Peripheral joint involvement 20 (24%) 32 (23%) 0.751 23 (22%) 9 (23%) 0.924
Psoriasis 14 (17%) 23 (16%) 0.779 17 (16%) 6 (14%) 0.716
Uveitis 18 (22%) 45 (31%) 0.159 31 (30%) 14 (33%) 0.742
IBD 7 (9%) 14 (10%) 0.804 9 (9%) 5 (12%) 0.552
TNFi 27 (33%) 49 (33%) 0.950 29 (28%) 20 (47%) 0.029
NSAID 51 (62%) 106 (72%) 0.121 76 (73%) 30 (70%) 0.684
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higher disease activity assessed by all markers except CRP, 
whilst ever-smoking was associated with higher ASDAS, 
ESR, and CRP (Table 3). Deprivation (IMD) was associated 
with worse BASFI, quality of life, and ESR.
Alcohol status showed significant interactions with both 
ever-smoking and A&D in this model. Stratification by ever-
smoking revealed an interaction between alcohol and A&D 
which was significant in ever-smokers but not in never-smok-
ers. Within the never-smoking subgroup, a strong association 
between alcohol and reduced disease severity was observed 
(Table 2). Ever-smokers who consumed alcohol reported 
reduced BASDAI and BASFI, only in the absence of A&D.
Disease activity, functional impairment, and quality of 
life were not significantly different between heavy and mod-
erate drinking. Sensitivity analyses using gender-specific 
tertiles also did not demonstrate an association between 
intake quantity and disease outcome measures. Multivariable 
logistic models of the dichotomised EQ5D index were not 
associated with alcohol status or quantity (data not shown).
Discussion
Study of this cross-sectional axSpA cohort demonstrated 
an inverse association between alcohol drinking and dis-
ease activity and functional impairment. The association 
between alcohol and disease activity was in contrast to, and 
independent of, the detrimental effects of smoking, depres-
sion, and deprivation. A lower BASDAI of 0.8 to 1.6 is 
clinically relevant, as ≥ 2-unit improvement is considered 
a response to TNFi therapy [16]. In never-smokers, alcohol 
was associated with still greater reduction in disease activity. 
Table 2  Multivariable linear models comparing disease activity, functional impairment, and quality of life between alcohol drinkers and non-
drinkers, adjusting for age, gender, symptom duration, use of TNFi, ever-smoking, IMD, and A&D
Statistically significant results are presented in bold
Total sample size for each regression model was 213 for BASDAI, BASFI and spinal pain, 181 for ASDAS, 206 EQ-VAS, 179 CRP, and 204 
ESR
BASDAI Bath ankylosing spondylitis disease activity index, ASDAS Ankylosing Spondylitis Disease Activity Score, BASFI Bath AS functional 
index, EQ-VAS EuroQol visual analogue scale, TNFi TNF inhibitor, IMD index of multiple deprivation, A&D anxiety and depression
a Model: y = alcohol + age + gender + symptom duration + TNFi + eversmoking + IMD + A&D
b Model: y = alcohol + age + gender + symptom duration + TNFi + IMD + A&D + alcohol*A&D
β coefficient (95% CI) 
without interaction  termsa
β coefficient (95% CI) in never-smokersb β coefficient (95% CI) in ever-smokers if A&D 
is  absentb
if A&D is present if A&D is absent if A&D is present if A&D is absent
BASDAI − 0.83 (− 1.49, − 0.17) 0.58 (− 0.66, 1.83) − 1.69 (− 2.93, − 0.45) 0.32 (− 1.24, 1.88) − 1.64 (− 3.24, − 0.05)
ASDAS − 0.36 (− 0.66, − 0.05) 0.24 (− 0.36, 0.84) − 0.60 (− 1.18, − 0.02) 0.35 (− 0.32, 1.02) − 0.71 (− 1.41, − 0.01)
Spinal pain − 0.79 (− 1.56, − 0.02) 0.44 (− 0.97, 1.84) − 2.11 (− 3.51, − 0.71) 1.10 (− 0.79, 2.98) − 0.44 (− 2.37, 1.49)
BASFI − 1.40 (− 2.12, − 0.68) − 0.18 (− 1.52, 1.15) − 2.25 (− 3.57, − 0.92) 0.14 (− 1.56, 1.84) − 2.46 (− 4.20, − 0.73)
EQ-VAS − 7.46 (− 13.6, − 1.34) 11.4 (− 1.18, 24.0) − 13.9 (− 26.4, − 1.36) 10.8 (− 2.98, 24.6) − 7.84 (− 22.0, 6.33)
Ln(CRP) − 0.19 (− 0.56, 0.19) − 0.07 (− 0.78, 0.63) − 0.13 (− 0.84, 0.57) 0.26 (− 0.67, 1.19) − 0.55 (− 1.51, 0.42)
Ln(ESR) − 0.15 (− 0.44, 0.15) − 0.10 (− 0.61, 0.41) − 0.06 (− 0.57, 0.45) 0.53 (− 0.22, 1.29) − 0.11 (− 0.88, 0.67)
Table 3  Effect sizes of anxiety 
and depression, ever-smoking, 
and index of deprivation as 
covariates in multivariable 
models of alcohol and disease 
activity, functional impairment, 
and quality of life
Statistically significant results are presented in bold
Total sample size for each regression model was 213 for BASDAI, BASFI, and spinal pain, 181 for 
ASDAS, 206 EQ-VAS, 179 CRP, and 204 ESR
BASDAI Bath ankylosing spondylitis disease activity index, ASDAS Ankylosing Spondylitis Disease Activ-
ity Score, BASFI Bath AS functional index, EQ-VAS EuroQol visual analogue scale
Anxiety and depression Ever-smoking Index of multiple deprivation
BASDAI 1.68 (1.01, 2.31) 0.62 (− 0.02, 1.26) − 0.07 (− 0.19, 0.04)
ASDAS 0.75 (0.44, 1.06) 0.51 (0.21, 0.81) − 0.03 (− 0.08, 0.02)
Spinal pain 1.70 (0.94, 2.45) 0.47 (− 0.28, 1.22) − 0.12 (− 0.26, 0.01)
BASFI 1.78 (1.08, 2.48) 0.51 (− 0.19, 1.20) − 0.14 (− 0.27, − 0.02)
EQ-VAS 19.9 (14.0, 25.8) 2.22 (− 3.62, 8.07) − 1.83 (− 2.88, − 0.79)
Ln(CRP) 0.30 (− 0.07, 0.66) 0.45 (0.08, 0.81) 0.05 (− 0.02, 0.11)
Ln(ESR) 0.32 (0.03, 0.61) 0.37 (0.08, 0.65) 0.07 (0.02, 0.12)
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In ever-smokers, A&D appears to counteract the reduced 
disease activity seen with alcohol use. This is interesting, 
since alcohol and depression each increase the risk of the 
other and yet appear to have opposing effects on disease 
activity in axSpA patients.
Only two studies have explored alcohol consumption in 
axSpA. In a cross-sectional study, Zhang et al. focused on 
BASDAI (dichotomised at 4) and found increased odds of 
high BASDAI in moderate drinkers compared to non-drink-
ers, but analyses did not account for treatment or A&D and 
was not significant when adjusted for smoking [17]. Blachier 
et al. reported significantly increased odds of drinking in 
axSpA patients with radiographic changes at the sacroiliac 
joints and/or vertebrae [4]. The covariates were not explicit 
stated but did not include A&D, and no comments were 
made on disease activity.
In addition to more frequently reporting alcohol drink-
ing, male patients were also more frequently categorised as 
heavy drinkers, which is consistent with population studies. 
Male gender in axSpA studies is usually associated with 
more severe disease. The finding that disease activity and 
functional impairment were both lower in alcohol drinkers, 
despite this male gender preponderance, is interesting.
Within the subgroup of participants reporting alcohol 
use, increasing tertiles of alcohol exposure was not asso-
ciated with improved axSpA disease measures. This lack 
of dose–response effect is less suggestive of a biological 
protective effect from alcohol consumption. However, the 
relationship between alcohol intake and inflammation in 
population studies typically follows a U-shaped distribu-
tion with modest intake conferring protection which is lost 
at higher levels of alcohol consumption [18]. It is possible 
that the lack of association between axSpA disease measures 
with amount of alcohol consumed in this study could be 
due to the same phenomenon. Alcohol has been shown to 
suppress production of proinflammatory cytokines such as 
TNF and IL6 in human cell models, and moderate alcohol 
consumption is associated with lower levels of CRP, IL6, 
and soluble TNF receptors in healthy adults [19, 20]. Further 
study in larger disease population is required to explore this 
in more detail.
No associations between alcohol drinking and any extra-
articular disease manifestations were seen in this study. This 
differs from the previous studies which have highlighted the 
association between alcohol use and disease susceptibility 
to psoriasis and psoriatic arthritis [11, 12].
There was no difference in self-reported A&D symptoms 
between drinkers and non-drinkers. This was not consist-
ent with other studies where non-drinkers were less likely 
to develop A&D [21]. Self-reported A&D was signifi-
cantly associated with worse disease activity and functional 
impairment with effect sizes larger than smoking or depriva-
tion. There was no association between ever-smoking and 
drinking. However, heavy drinkers were more frequently 
smokers, which is consistent with general population studies 
showing a dose-dependent relationship between alcohol use 
and smoking [22]. Interestingly, ever-smoking was associated 
with only ASDAS, CRP, and ESR, but none of the other more 
subjective disease activity markers in multivariable models. 
Smoking’s previous reported effect on the Bath indices may 
be explained by confounding factors accounted for in this 
study. There was no difference in deprivation between alcohol 
status. However, increasing deprivation was independently 
associated with worse BASFI and quality of life. Despite the 
detrimental effects of smoking, depression, and deprivation, 
we observed lower disease activity and functional impair-
ment in drinkers when these factors were adjusted for.
Studies of alcohol’s impact on health outcomes often 
report unexpected and conflicting results [23]. These incon-
sistencies may be explained by several methodological limi-
tations. First, there are many confounders that should be 
considered. Alcohol drinking, depression, smoking, and 
socioeconomic status (SES) are interlinked and each have 
well-known effects on disease severity. The strength of this 
study is that these factors were adjusted for. However, this 
study cohort was recruited from an area with generally high 
levels of deprivation. Future studies should recruit a more 
mixed population. Second, many alcohol studies have been 
criticised for the heterogeneity of their non-drinker com-
parator, which often included occasional drinkers [23]. For 
this reason, two common responses—social and occasional 
drinking—were classified as drinkers in this study to pro-
vide a more homogenous comparator group. However, we 
were unable to perform sensitivity analyses of different cat-
egorisations. Third, it has been shown that alcohol intake 
is underestimated in surveys due to social desirability bias 
[23]. This study may be more susceptible to this bias given 
information was collected during clinical consultations. This 
may explain the low number of ex-drinkers. Like most alco-
hol studies, we focused on volume rather than frequency or 
quality. Future studies should distinguish patterns of drink-
ing (such as binge-drinking) and also type of alcohol con-
sumed (such as spirits, wines, beers). Wines are of particular 
interest as they are rich in anti-inflammatory polyphenols, 
such as resveratrol. These compounds inhibit TNF-induced 
nuclear factor kappa B (NF-κB) activation and may have 
protective properties in inflammatory arthritides [24].
The main limitation of this study was its cross-sectional 
design, which does not allow change in drinking behaviour 
to be considered. First, it is possible that those with more 
challenging disease activity may modify their behaviour 
and reduce alcohol intake to improve coping mechanisms. 
Second, studies have shown that measuring alcohol con-
sumption during one time period in a participant’s life may 
be unreliable [6]. Repeated assessments of alcohol intake 
should be considered in future studies.
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In conclusion, this study is the first to report that alcohol 
consumption is associated with reduced measures of axSpA 
disease severity than in non-drinkers. Further studies are 
needed to establish a causal link. These results cannot be 
used to endorse or promote the use of alcohol as both scien-
tific evidence and guidelines are increasingly downplaying 
the previously held belief that moderate alcohol is beneficial. 
Furthermore, alcohol intake of three or more units per day 
is a recognised risk factor for osteoporosis [25], which is an 
important complication in axSpA.
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